Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07672561
PHASE3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Sponsor: Zhejiang Wenda Pharma Technology LTD.

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

375

Start Date

2026-03-18

Completion Date

2027-07-30

Last Updated

2026-06-29

Healthy Volunteers

Yes

Interventions

DRUG

Drug:WD-890

WD-890 tablet will be administered orally.

DRUG

Drug: placebo

Placebo tablet will be administered orally.

Locations (1)

Hospital of Dermatology, Chinese Academy of Medical Sciences

Nanjing, Jiangsu, China